Skip to main content
SpringerLink
Log in

Individualising Therapy for Older Adults with Diabetes Mellitus

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

The goal when treating patients with diabetes mellitus is to achieve the maximum longevity consistent with an optimal quality of life. To achieve this goal, treatment is typically focused on management of hyperglycaemic symptoms and prevention of microvascular and macrovascular complications. While appropriate for most individuals, including many older adults with robust health, this focus is often too limited for older adults facing diminished life expectancy and co-existing medical illness, frailty and disability. Creating a treatment plan that optimises health and function, and reduces the risk for morbidity and mortality, requires individualised therapy that judiciously manages symptoms and multiple competing health risks while remaining consistent with the patient’s or his/her caregiver’s healthcare preferences. Physicians caring for older adults with diabetes must be adept at recognising conditions commonly associated with diabetes, including the interplay with co-morbid illness, and be able to assess the patient’s health status and use this information to recommend a treatment plan that is consistent with the patient’s personal goals for care.

The majority of older adults with diabetes will benefit from management of cardiovascular risk, including intensive management of hypertension, lipids, use of aspirin (acetylsalicylic acid) and smoking cessation, and screening for common geriatric syndromes. For a significant minority of older adults with life expectancy of ≥10 years, it is reasonable to consider intensive management of hyperglycaemia (glycosylated haemoglobin [HbA1c] target ≤7%). For frail older adults with life expectancy of ≤5 years, strategies for reducing medical burden, improving function and moderate glucose control (HbA1c ≈8%) is reasonable and sufficient to control hyperglycaemic symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Sinclair A. Clinical guidelines for type 2 diabetes mellitus. European Diabetes Working Party for Older People, 2001–2004 [online]. Available from URL: http://www.eugms.org/documents/clinicalguidelinediabetes.pdf [Accessed 2007 Aug 23]

  2. Park E, Durso SC, Confessore GJ. A case study of educational practices for the aging global population. Lifelong Educ Lib 2006; 6: 67–79

    Google Scholar 

  3. Landefeld CS, Callahan CM, Woolard N. General internal medicine and geriatrics: building a foundation to improve the training of general internists in the care of older adults. Ann Intern Med 2003; 139(7): 609–14

    PubMed  Google Scholar 

  4. National Diabetes Information Clearinghouse. National diabetes statistics [online]. Available from URL: http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm [Accessed 2007 Aug 23]

  5. Durso SC. Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA 2006; 295(16): 1935–40

    Article  PubMed  CAS  Google Scholar 

  6. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51 (5 Suppl. Guidelines): S265–80

    Article  PubMed  Google Scholar 

  7. Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients’ preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis. BMJ 2000; 320(7246): 1380–4

    Article  PubMed  CAS  Google Scholar 

  8. Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000; 320(7231): 341–6

    Article  PubMed  CAS  Google Scholar 

  9. Arora NK, McHorney CA. Patient preferences for medical decision making: who really wants to participate? Med Care 2000; 38(3): 335–41

    Article  PubMed  CAS  Google Scholar 

  10. Say RE, Thomson R. The importance of patient preferences in treatment decisions: challenges for doctors. BMJ 2003; 327(7414): 542–5

    Article  PubMed  Google Scholar 

  11. Epstein RM, Alper BS, Quill TE. Communicating evidence for participatory decision making. JAMA 2004; 291(19): 2359–66

    Article  PubMed  CAS  Google Scholar 

  12. Vijan S, Hayward RA, Ronis DL, et al. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 2005; 20(5): 479–82

    Article  PubMed  Google Scholar 

  13. Huang ES, Gorawara-Bhat R, Chin MH. Self-reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc 2005; 53(2): 306–11

    Article  PubMed  Google Scholar 

  14. Maddigan SL, Feeny DH, Majumdar SR, et al. Understanding the determinants of health for people with type 2 diabetes. Am J Public Health 2006; 96(9): 1649–55

    Article  PubMed  Google Scholar 

  15. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 2005; 14(5): 1311–20

    Article  PubMed  Google Scholar 

  16. Deaton C, Kimble LP, Veledar E, et al. The synergistic effect of heart disease and diabetes on self-management, symptoms, and health status. Heart Lung 2006; 35(5): 315–23

    Article  PubMed  Google Scholar 

  17. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med 2002; 162(20): 2269–76

    Article  PubMed  Google Scholar 

  18. Niefeld MR, Braunstein JB, Wu AW, et al. Preventable hospitalization among elderly Medicare beneficiaries with type 2 diabetes. Diabetes Care 2003; 26(5): 1344–9

    Article  PubMed  Google Scholar 

  19. Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Aff (Millwood) 2001; 20(6): 233–41

    Article  CAS  Google Scholar 

  20. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006; 29(3): 725–31

    Article  PubMed  Google Scholar 

  21. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294(6): 716–24

    Article  PubMed  CAS  Google Scholar 

  22. Standards of medical care in diabetes: 2006. Diabetes Care 2006; 29Suppl. 1: 4–42

    Google Scholar 

  23. Katon WJ, Von Korff M, Lin EH, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch Gen Psychiatry 2004; 61(10): 1042–9

    Article  PubMed  Google Scholar 

  24. Harman JS, Edlund MJ, Fortney JC, et al. The influence of comorbid chronic medical conditions on the adequacy of depression care for older Americans. J Am Geriatr Soc 2005; 53(12): 2178–83

    Article  PubMed  Google Scholar 

  25. Fenton JJ, Von Korff M, Lin EH, et al. Quality of preventive care for diabetes: effects of visit frequency and competing demands. Ann Fam Med 2006; 4(1): 32–9

    Article  PubMed  Google Scholar 

  26. Wray LA, Ofstedal MB, Langa KM, et al. The effect of diabetes on disability in middle-aged and older adults. J Gerontol A Biol Sci Med Sci 2005; 60(9): 1206–11

    Article  PubMed  Google Scholar 

  27. Volpato S, Blaum C, Resnick J, et al. Comorbidities and impairments explaining the association between diabetes and lower extremity disability: the Women’s Health and Aging Study. Diabetes Care 2002; 25(4): 678–83

    Article  PubMed  Google Scholar 

  28. Blaum CS, Ofstedal MB, Langa KM, et al. Functional status and health outcomes in older Americans with diabetes mellitus. J Am Geriatr Soc 2003; 51(6): 745–53

    Article  PubMed  Google Scholar 

  29. Volpato S, Ferrucci L, Blaum C, et al. Progression of lower-extremity disability in older women with diabetes: the Women’s Health and Aging Study. Diabetes Care 2003; 26(1): 70–5

    Article  PubMed  Google Scholar 

  30. Covinsky KE, Hilton J, Lindquist K, et al. Development and validation of an index to predict activity of daily living dependence in community-dwelling elders. Med Care 2006; 44(2): 149–57

    Article  PubMed  Google Scholar 

  31. Maty SC, Fried LP, Volpato S, et al. Patterns of disability related to diabetes mellitus in older women. J Gerontol A Biol Sci Med Sci 2004; 59(2): 148–53

    Article  PubMed  Google Scholar 

  32. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154(7): 635–41

    Article  PubMed  CAS  Google Scholar 

  33. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61(5): 661–6

    Article  PubMed  Google Scholar 

  34. Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance. Neurology 1999; 52(5): 971–5

    Article  PubMed  CAS  Google Scholar 

  35. Feil D, Weinreb J, Sultzer D. Psychiatric disorders and psychotropic medication use in elderly persons with diabetes. Ann Long Term Care 2006; 14(7): 39–47

    Google Scholar 

  36. Brown JS, Vittinghoff E, Lin F, et al. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001–2002. Diabetes Care 2006; 29(6): 1307–12

    Article  PubMed  Google Scholar 

  37. Volpato S, Leveille SG, Blaum C, et al. Risk factors for falls in older disabled women with diabetes: the Women’s Health and Aging Study. J Gerontol A Biol Sci Med Sci 2005; 60(12): 1539–45

    Article  PubMed  Google Scholar 

  38. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002; 324(7353): 1577–80

    Article  PubMed  Google Scholar 

  39. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001; 285(21): 2750–6

    Article  PubMed  CAS  Google Scholar 

  40. Lee SJ, Lindquist K, Segal MR, et al. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA 2006; 295(7): 801–8

    Article  PubMed  CAS  Google Scholar 

  41. Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003; 138(3): 215–29

    PubMed  Google Scholar 

  42. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003; 138(7): 593–602

    PubMed  Google Scholar 

  43. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 2004; 140(8): 650–8

    PubMed  CAS  Google Scholar 

  44. Knopp RH, d’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29(7): 1478–85

    Article  PubMed  CAS  Google Scholar 

  45. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353(3): 238–48

    Article  PubMed  CAS  Google Scholar 

  46. Tinetti ME. Clinical practice: preventing falls in elderly persons. N Engl J Med 2003; 348(1): 42–9

    Article  PubMed  Google Scholar 

  47. Tinetti ME, Doucette J, Claus E, et al. Risk factors for serious injury during falls by older persons in the community. J Am Geriatr Soc 1995; 43(11): 1214–21

    PubMed  CAS  Google Scholar 

  48. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994; 331(13): 821–7

    Article  PubMed  CAS  Google Scholar 

  49. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005; 16(5): 468–74

    Article  PubMed  CAS  Google Scholar 

  50. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53

    Google Scholar 

  51. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; (1): CD002967

  52. Black J, Cefalu CA, Durso SC, et al. Diabetes mellitus: oral antidiabetic agents, insulin, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and calcium channel blockers. In: Geriatric pharmaceutical care guidelines: a clinical and cost reference tool for use in geriatric care. Covington (KY): Omnicare, 2005: 185–204

    Google Scholar 

  53. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137(1): 25–33

    PubMed  CAS  Google Scholar 

  54. Nisbet JC, Sturtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust 2004; 180(2): 53–4

    PubMed  Google Scholar 

  55. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003; 326(7379): 4–5

    Article  PubMed  CAS  Google Scholar 

  56. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50(6): 735–41

    Article  PubMed  Google Scholar 

  57. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157(15): 1681–6

    Article  PubMed  CAS  Google Scholar 

  58. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985; 33(4): 278–85

    PubMed  CAS  Google Scholar 

  59. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005; 28(7): 601–31

    Article  PubMed  CAS  Google Scholar 

  60. Greco D, Angileri G. Drug-induced severe hypoglycaemia in type 2 diabetic patients aged 80 years or older. Diabetes Nutr Metab 2004; 17(1): 23–6

    PubMed  CAS  Google Scholar 

  61. Physicians’ desk reference (2004). 58th ed. Montvale (NJ): Thomson PDR, 2004: 718–20, 742–3, 2603–4

  62. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J Diabetes Complicat 2004; 18(1): 60–8

    Article  PubMed  Google Scholar 

  63. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44(7): 751–5

    PubMed  CAS  Google Scholar 

  64. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17(6): 467–73

    Article  PubMed  CAS  Google Scholar 

  65. US FDA. Code of federal regulations. Title 21, Volume 5. Subpart E: Requirements for specific new drugs or devices. Sec. 310.517: labeling for oral hypoglycemic drugs of the sulfonylurea class [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFR-Search.cfm?fr=310.517 [Accessed 2007 23 Aug]

  66. Haas L. Management of diabetes mellitus medications in the nursing home. Drugs Aging 2005; 22(3): 209–18

    Article  PubMed  CAS  Google Scholar 

  67. Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006; 55 (5 Suppl. 1): S16–9

    Article  PubMed  CAS  Google Scholar 

  68. Del Prato S, Heine RJ, Keilson L. Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care 2003; 26(7): 2075–80

    Article  PubMed  Google Scholar 

  69. Papa G, Fedele V, Rizzo MR. Safety of type 2 diabetes treatment with epaglinide compared with glibenclamide in elderly people. Diabetes Care 2006; 29: 1918–20

    Article  PubMed  CAS  Google Scholar 

  70. Marbury TC, Ruckle JL, Hatorp V, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 2000; 67(1): 7–15

    Article  PubMed  CAS  Google Scholar 

  71. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Comparative effectiveness review No. 8 prepared by Johns Hopkins Evidence-based Practice Center under contract No. 209-02-0018. Rockville (MD). Agency for Healthcare Research and Quality, 2007 Jul [online]. Available from URL: http://effectivehealthcare.ahrq.gov/repFiles/OralFullReport.pdf [Accessed 2007 Aug 23]

    Google Scholar 

  72. Abramowicz M, Zuccotti G. Drugs for diabetes. Treat Guidel Med Lett 2005 Aug; 3(36): 57–62

    PubMed  Google Scholar 

  73. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27(1): 256–63

    Article  PubMed  CAS  Google Scholar 

  74. US FDA. GlaxoSmithKline letter [online]. Available from URL: http://www.fda.gov/medwatch/safety/2006/Avandia_DHCPletter.pdf [Accessed 2006 Nov 21]

  75. Beebe K, Patel J. Rosiglitazone is effective and well-tolerated in patients ≥65 years with type 2 diabetes [abstract]. Diabetes 1999; 42(SI): A111

    Google Scholar 

  76. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet 2005; 366(9493): 1279–89

    Article  PubMed  CAS  Google Scholar 

  77. Isley WL. Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. ACP J Club 2006; 144(2): 34

    PubMed  Google Scholar 

  78. Willms B, Rugge D. Comparison of acarbose and metformin in patients with type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study. Diabet Med 1999; 16: 751–66

    Article  Google Scholar 

  79. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98(5): 443–51

    Article  PubMed  CAS  Google Scholar 

  80. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7(1): 73–82

    Article  PubMed  Google Scholar 

  81. Inhaled insulin (Exubera). Med Lett Drugs Ther 2006; 48(1239): 57–8

    Google Scholar 

  82. DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28(8): 1922–8

    Article  PubMed  CAS  Google Scholar 

  83. Quattrin T, Belanger A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622–7

    Article  PubMed  CAS  Google Scholar 

  84. Rosenstock J, Cappelleri JC, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 2013–8

    Google Scholar 

  85. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47(1210): 45–6

    Google Scholar 

  86. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006; 60(11): 1454–70

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge that Dr Durso is supported as a Miller-Coulson Scholar, and that Dr Boyd is supported as a Johns Hopkins Bayview Scholar in the Center for Innovative Medicine. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, 5505 Hopkins Bayview Circle, Baltimore, Maryland, 21224, USA

    Danelle Cayea, Cynthia Boyd &  Samuel C. Durso

Authors
  1. Danelle Cayea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cynthia Boyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samuel C. Durso
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel C. Durso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cayea, D., Boyd, C. & Durso, S.C. Individualising Therapy for Older Adults with Diabetes Mellitus. Drugs Aging 24, 851–863 (2007). https://doi.org/10.2165/00002512-200724100-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200724100-00005

Keywords

Search

Navigation